Skip to content
navbar-toggler
Home
About
Lumira Ventures
Our Values
Foundation
Team
Our Team
Venture Fellows
Portfolio
Stories
News
Login
Cardiovascular Disease Shouldn't Go Undetected For Women.
More Accurate Solutions For Life-Saving Care.
Coronary Artery Disease Diagnosed And Treated
- Now With Confidence.
Lupus Nephritis Can Be Devastating.
LUPKYNIS™ - Reducing The Need For Kidney Transplants.
Robotic Joint Replacement Surgery -
Less Invasive, Highly Successful.
Can Chronic Kidney Disease Be Made Manageable?
Absolutely.
Disruptive Cancer Therapies -
Made To Make A Difference.
Active Epileptic Seizures Can Now
Be Terminated On Demand.
Chemotherapy Without Destroying Your Immune System?
COSELA® (trilaciclib) Has It Conquered.
Spinal Disc Failure Shouldn't Be Limiting.
M6-C™ Artificial Disc Replacement Accurately Replicates The Natural Disc.
No Longer A Chronic Life-Long Disease -
Hepatitis C Cured.
Performance is More Than Just Great Returns To Our Investors.
It Is Also Measured By Impact.
40+ Diseases Targeted
35+ Approved Products
$75+ Billion Cumulative Revenue from Approved Products
Over 5 Million Patients Treated
$6+ Billion Capital Raised by Portfolio Companies
Toronto (Head Office)
141 Adelaide Street Suite 770 Toronto, ON Canada, M5H 3L5
Montréal
Espace CDPQ 3, Place Ville Marie Bureau 12350, Niveau L Montreal, QC Canada, H3B 0E7
Vancouver
Vancouver, BC Canada
Boston
303 Wyman Street Suite 300 Waltham, MA, USA, 02451-1208
Scroll to Top